Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in Alzheimer's & Dementia: Translational ...
Scientists are urgently seeking fluid biomarkers for frontotemporal dementia, the most common dementing illness among 40- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback